Monday, February 15, 2016 12:14:03 PM
UCLA has rights to the GBM patent pursuit too (it's not an executed patent). They're listed on it as well, as is Cognate. They pursued it based on preclinical DCVax-L +checkpoint data. When I did the search for the post, I did under Direct discussions but this CI patent has nothing to do with Direct.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116745636&txt2find=Direct%7Cpatent
COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER
A combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, the efficacy of anti-tumor immune responses or a medically beneficial response by a tumor.
Bosch, Marnix Leo (Clyde Hill, WA, US)
Ganjel, James Kelly (Bethesda, MD, US)
Powers, Linda F. (Bethesda, MD, US)
Liau, Linda M. (Los Angeles, CA, US)
Prins, Robert M. (Pacific Palisades, CA, US)
COGNATE BIOSERVICES, INC.
NORTHWEST BIOTHERAPEUTICS
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
REVIMMUNE, INC.
But it makes me wonder how many other patents in their portfolio is not sole owned by NWBO. Is there really a reason to have NWBO patents owned by COI parties?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116745636&txt2find=Direct%7Cpatent
COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER
A combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, the efficacy of anti-tumor immune responses or a medically beneficial response by a tumor.
Bosch, Marnix Leo (Clyde Hill, WA, US)
Ganjel, James Kelly (Bethesda, MD, US)
Powers, Linda F. (Bethesda, MD, US)
Liau, Linda M. (Los Angeles, CA, US)
Prins, Robert M. (Pacific Palisades, CA, US)
COGNATE BIOSERVICES, INC.
NORTHWEST BIOTHERAPEUTICS
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
REVIMMUNE, INC.
But it makes me wonder how many other patents in their portfolio is not sole owned by NWBO. Is there really a reason to have NWBO patents owned by COI parties?
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
